Cardinal Health CEO on Obamacare Subsidies, Drug Pricing, and Business Growth

Obamacare Subsidies and Healthcare Access

• 📌 Cardinal Health CEO Jason Hollar stated that the extension of Obamacare subsidies is reviewed "every single day" due to its potential impact.
• 💡 The company supports government efforts to ensure affordable healthcare access without sacrificing innovation.
• ⚠️ Approximately 4 million Americans could lose health coverage if subsidies are not extended, representing about 1% of insured Americans.
• 📊 While not minimizing individual impact, this figure is seen as not having a material impact on the pharmaceutical industry.

Business Performance and Growth Drivers

• 🚀 Cardinal Health reported strong quarterly results, with its pharmaceutical and specialty solutions segment revenue up 23% year-over-year to $59 billion.
• ✅ This growth is attributed to strong utilization across generic and specialized products and effective operational execution by the Cardinal Health team.
• 📈 All five of Cardinal Health's operating segments experienced significant double-digit earnings growth, highlighting the company's broad strength.

Drug Pricing and Policy Impact

• 🎯 Regarding President Trump's focus on lowering drug costs, Cardinal Health views its operations as coordinated with broader industry efforts.
• 🧩 The 90/10 rule is highlighted: 90% of pharmaceutical volume is in generics (10% of cost), while 10% of volume is in branded products (90% of cost).
• 💰 Cardinal Health, as a fee-for-service organization, does not set drug prices and is therefore largely unaffected by direct drug pricing policies for branded products.
• 🤝 The company is aligned with the administration and the American people on increasing access and affordability in healthcare, benefiting their business through increased volume.